Over the past few years, there has been an influx of cluster of innovative cancer therapies for the patients but the heightened excitement that immunotherapy market has brought for wide variety of tumor types is approaching one-size-fits-all approach.
Global CD47 Inhibitor Drug Clinical Trials Insight 2028 Report Highlights:
- CD47 Inhibitor Drug Market Trends & Future Prospects
- Insight On More Than 50 CD47 Inhibitors Drugs In Clinical Trials
- Orphan, Fast Track, Breakthrough Therapy Designation Insight
- Insight On CD47 Inhibitors Drugs Biomarkers Sourced During Clinical Trials
- CD47 Inhibitors Drug Clinical Trials Insight By Company, Indication & Phase
- CD47 Inhibitors Drug Clinical Trials Insight As Mono & Combination Therapy
- Global CD47 Inhibitor Drug Market Dynamics
Download Report Sample: https://www.kuickresearch.com/report-cd47-inhibitor-drugs-clinical-trials
Over the past few years, there has been an influx of cluster of innovative cancer therapies for the patients but the heightened excitement that immunotherapy market has brought for wide variety of tumor types is approaching one-size-fits-all approach. However, despite these huge advancements in the field of cancer therapeutics, the majority of patients does not respond to or develop resistance to immunotherapy, highlighting the need for additional approaches to expand cancer immunotherapy. Researchers have conducted several clinical studies to identify the process through which evolving tumor cells can overcome innate immunity. Among several pathophysiologic mechanisms, CD47 has emerged out to of great interest.
During the past few years, various leading companies involved CD47 targeting approach in their clinical pipeline and several collaboration and partnerships are observed in this segment. The main aim of the collaborations is to speed up the process of drug approval and development in leading pharmaceutical regions so that the manufacturer and the patient gets maximum outcomes with less duration of time. The current CD47 targeting therapy market is dominated by the Gilead, which attracts other leading pharmaceutical companies and results in increasing investments in this sector.
For instance in 2021, MacroGenics also entered into research collaboration and license agreement with Zai Lab in 2021. Under this, Zai Lab obtains exclusive licenses from MacroGenics to develop, manufacture and commercialize two additional molecules. For the four programs, each company will contribute intellectual property to generate either CD3- or CD47-based bispecific antibodies. Another, Pfizer completed the acquisition of Trillium Therapeutics. Under the terms, Pfizer will gain exclusive rights to develop and commercialize two lead molecules, TTI-622 and TTI-621, block the signal-regulatory protein α (SIRPα)–CD47 axis, which is emerging as a key immune checkpoint in hematological malignancies.
The robust clinical pipeline of CD47 targeting therapies is one of the major reasons governing the growth of the market during the forecast period. The promising preclinical studies have gained interest from pharmaceutical giants to initiate research and development in this segment. The pipeline of CD47 targeting therapies is highly crowded, consisting of several potential candidates including Magrolimab, ZL1201, STI-6643, AK117, IBI188, CC-9002, IB188, DSP107, AL008, and others. Magrolimab is one of the most advanced stage product which is expected to gain approval by 2024.
Although monotherapy with CD47 targeting agents have shown promising results, enhanced efficacy has been demonstrated in combination therapies. It is believed that combination therapies will outshine the cancer therapeutics market in the coming years which is mainly due to synergistic mechanism of action of combined drugs and overcome the issue of drug resistance. The potential role of CD47 targeting therapies in combination has led to initiation of several clinical trials, which will also have a positive impact on the growth of market. For example, ALX Oncology in collaboration with Eli Lilly to evaluate the combination of ALX148, a next generation CD47 blocker and Cyramza for the treatment of patients with HER2-positive gastric cancer or gastroesophageal junction cancer. Under the terms, ALX Oncology will conduct phase-II/III trial while Eli Lilly will supply Cyramza for the trial.
Contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366